BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis. 2012;12:207. [PMID: 22954038 DOI: 10.1186/1471-2334-12-207] [Cited by in Crossref: 97] [Cited by in F6Publishing: 92] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Remington LT, Sligl WI. Community-acquired pneumonia. Curr Opin Pulm Med 2014;20:215-24. [PMID: 24614242 DOI: 10.1097/MCP.0000000000000052] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
2 Mo X, Gai Tobe R, Liu X, Mori R. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China. Pediatric Infectious Disease Journal 2016;35:e353-61. [DOI: 10.1097/inf.0000000000001288] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
3 Zhu F, Hu Y, Liang Q, Young M Jr, Zhou X, Chen Z, Liang JZ, Gruber WC, Scott DA. Safety and tolerability of 13-valent pneumococcal conjugate vaccine in healthy Chinese adults, children and infants. Ther Adv Drug Saf 2015;6:206-11. [PMID: 26668712 DOI: 10.1177/2042098615613985] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Negus D, Taylor PW. A poly-γ-(D)-glutamic acid depolymerase that degrades the protective capsule of Bacillus anthracis. Mol Microbiol 2014;91:1136-47. [PMID: 24428662 DOI: 10.1111/mmi.12523] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
5 Otczyk DC, Cripps AW. Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines. Pneumonia (Nathan) 2013;2:2-15. [PMID: 31463182 DOI: 10.15172/pneu.2013.2/229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lin L, Wen SH, Guo SZ, Su XY, Wu HJ, Chong L, Zhang HL, Zhang WX, Li CC. Role of SIRT1 in Streptococcus pneumoniae-induced human β-defensin-2 and interleukin-8 expression in A549 cell. Mol Cell Biochem 2014;394:199-208. [PMID: 24894820 DOI: 10.1007/s11010-014-2095-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Scelfo C, Menzella F, Fontana M, Ghidoni G, Galeone C, Facciolongo NC. Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance. Vaccines (Basel) 2021;9:420. [PMID: 33922273 DOI: 10.3390/vaccines9050420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Krenke K, Sadowy E, Podsiadły E, Hryniewicz W, Demkow U, Kulus M. Etiology of parapneumonic effusion and pleural empyema in children. The role of conventional and molecular microbiological tests. Respir Med 2016;116:28-33. [PMID: 27296817 DOI: 10.1016/j.rmed.2016.05.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
9 Chevalier-Cottin EP, Ashbaugh H, Brooke N, Gavazzi G, Santillana M, Burlet N, Tin Tin Htar M. Communicating Benefits from Vaccines Beyond Preventing Infectious Diseases. Infect Dis Ther 2020;9:467-80. [PMID: 32583334 DOI: 10.1007/s40121-020-00312-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sheikh S, Biundo E, Courcier S, Damm O, Launay O, Maes E, Marcos C, Matthews S, Meijer C, Poscia A, Postma M, Saka O, Szucs T, Begg N. A report on the status of vaccination in Europe. Vaccine 2018;36:4979-92. [DOI: 10.1016/j.vaccine.2018.06.044] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 14.5] [Reference Citation Analysis]
11 Kaur R, Casey JR, Pichichero ME. Emerging Streptococcus pneumoniae Strains Colonizing the Nasopharynx in Children After 13-valent Pneumococcal Conjugate Vaccination in Comparison to the 7-valent Era, 2006-2015. Pediatr Infect Dis J 2016;35:901-6. [PMID: 27420806 DOI: 10.1097/INF.0000000000001206] [Cited by in Crossref: 65] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
12 Boccalini S, Varone O, Chellini M, Pieri L, Sala A, Berardi C, Bonanni P, Bechini A. Hospitalizations for pneumonia, invasive diseases and otitis in Tuscany (Italy), 2002-2014: Which was the impact of universal pneumococcal pediatric vaccination? Hum Vaccin Immunother 2017;13:428-34. [PMID: 27925848 DOI: 10.1080/21645515.2017.1264796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 McElligott M, Vickers I, Cafferkey M, Cunney R, Humphreys H. Non-invasive pneumococcal serotypes and antimicrobial susceptibilities in a paediatric hospital in the era of conjugate vaccines. Vaccine 2014;32:3495-500. [PMID: 24795223 DOI: 10.1016/j.vaccine.2014.04.047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
14 Navarro-Torné A, Dias JG, Hruba F, Lopalco PL, Pastore-Celentano L, Gauci AJ; Invasive Pneumococcal Disease Study Group. Risk factors for death from invasive pneumococcal disease, Europe, 2010. Emerg Infect Dis 2015;21:417-25. [PMID: 25693604 DOI: 10.3201/eid2103.140634] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
15 Kawai K, Adil EA, Barrett D, Manganella J, Kenna MA. Ambulatory Visits for Otitis Media before and after the Introduction of Pneumococcal Conjugate Vaccination. The Journal of Pediatrics 2018;201:122-127.e1. [DOI: 10.1016/j.jpeds.2018.05.047] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
16 Hakenbeck R. Discovery of β-lactam-resistant variants in diverse pneumococcal populations. Genome Med 2014;6:72. [PMID: 25473434 DOI: 10.1186/s13073-014-0072-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
17 Savrasova L, Krumina A, Cupeca H, Zeltina I, Villerusha A, Grope I, Viksna L, Dimina E, Balasegaram S. Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012-2018. Front Pediatr 2021;9:532489. [PMID: 34692599 DOI: 10.3389/fped.2021.532489] [Reference Citation Analysis]
18 Setchanova L, Murdjeva M, Stancheva I, Alexandrova A, Sredkova M, Stoeva T, Yoneva M, Kurchatova A, Mitov I. Serotype changes and antimicrobial nonsusceptibility rates of invasive and non-invasive Streptococcus pneumoniae isolates after implementation of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Bulgaria. Braz J Infect Dis 2017;21:433-40. [PMID: 28472614 DOI: 10.1016/j.bjid.2017.03.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
19 Li R, Huang L, Mo S, Li J, Zhou X, Chen Z, Liang J, Young M Jr, Giardina PC, Scott DA. Safety, tolerability, and immunogenicity of 7-valent pneumococcal conjugate vaccine in older infants and young children in China who are naive to pneumococcal vaccination: Results of a phase 4 open-label trial. Vaccine 2015;33:3580-5. [PMID: 26044498 DOI: 10.1016/j.vaccine.2015.05.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Ruiz-Aragón J, Márquez Peláez S, Molina-Linde JM, Grande-Tejada AM. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis. Vaccine 2013;31:5349-58. [PMID: 24055349 DOI: 10.1016/j.vaccine.2013.09.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
21 Martinelli D, Pedalino B, Cappelli MG, Caputi G, Sallustio A, Fortunato F, Tafuri S, Cozza V, Germinario C, Chironna M. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013. Hum Vaccin Immunother. 2014;10:33-39. [PMID: 24096297 DOI: 10.4161/hv.26650] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
22 Chiu SS, Ho PL, Khong PL, Ooi C, So LY, Wong WH, Chan EL. Population-based incidence of community-acquired pneumonia hospitalization in Hong Kong children younger than 5 years before universal conjugate pneumococcal immunization. J Microbiol Immunol Infect 2016;49:225-9. [PMID: 25070281 DOI: 10.1016/j.jmii.2014.05.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
23 Lanks CW, Musani AI, Hsia DW. Community-acquired Pneumonia and Hospital-acquired Pneumonia. Med Clin North Am 2019;103:487-501. [PMID: 30955516 DOI: 10.1016/j.mcna.2018.12.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
24 Szynczewska E, Chlebna-sokół D. Immunogenicity of Heptavalent Conjugate Vaccine Against Streptococcus pneumoniae in Premature Babies with Low Birth Weight. Pediatrics & Neonatology 2014;55:101-7. [DOI: 10.1016/j.pedneo.2013.06.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
25 Mittal R, Parrish JM, Soni M, Mittal J, Mathee K. Microbial otitis media: recent advancements in treatment, current challenges and opportunities. J Med Microbiol 2018;67:1417-25. [PMID: 30084766 DOI: 10.1099/jmm.0.000810] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
26 Imöhl M, Reinert RR, van der Linden M. Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany. International Journal of Medical Microbiology 2015;305:776-83. [DOI: 10.1016/j.ijmm.2015.08.031] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
27 Ahl J, Littorin N, Forsgren A, Odenholt I, Resman F, Riesbeck K. High incidence of septic shock caused by Streptococcus pneumoniae serotype 3--a retrospective epidemiological study. BMC Infect Dis 2013;13:492. [PMID: 24148181 DOI: 10.1186/1471-2334-13-492] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
28 Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis 2015;15:419. [PMID: 26468008 DOI: 10.1186/s12879-015-1147-x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 11.7] [Reference Citation Analysis]
29 Boeddha NP, Schlapbach LJ, Driessen GJ, Herberg JA, Rivero-Calle I, Cebey-López M, Klobassa DS, Philipsen R, de Groot R, Inwald DP, Nadel S, Paulus S, Pinnock E, Secka F, Anderson ST, Agbeko RS, Berger C, Fink CG, Carrol ED, Zenz W, Levin M, van der Flier M, Martinón-Torres F, Hazelzet JA, Emonts M; EUCLIDS consortium. Mortality and morbidity in community-acquired sepsis in European pediatric intensive care units: a prospective cohort study from the European Childhood Life-threatening Infectious Disease Study (EUCLIDS). Crit Care 2018;22:143. [PMID: 29855385 DOI: 10.1186/s13054-018-2052-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 12.8] [Reference Citation Analysis]
30 Christophe BL, Mott M, da Cunha G, Caierão J, D Azevedo P, Dias C. Characterisation of Streptococcus pneumoniae isolates from invasive disease in adults following the introduction of PCV10 in Brazil. J Med Microbiol 2018;67:687-94. [PMID: 29533176 DOI: 10.1099/jmm.0.000717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Guzman-Holst A, de Barros E, Rubio P, DeAntonio R, Cintra O, Abreu A. Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020. Hum Vaccin Immunother 2021;:1-17. [PMID: 33735585 DOI: 10.1080/21645515.2021.1879578] [Reference Citation Analysis]
32 Balaji V, Jayaraman R, Verghese VP, Baliga PR, Kurien T. Pneumococcal serotypes associated with invasive disease in under five children in India & implications for vaccine policy. Indian J Med Res 2015;142:286-92. [PMID: 26458344 DOI: 10.4103/0971-5916.166588] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
33 Tóthpál A, Kardos S, Laub K, Nagy K, Tirczka T, van der Linden M, Dobay O. Radical serotype rearrangement of carried pneumococci in the first 3 years after intensive vaccination started in Hungary. Eur J Pediatr 2015;174:373-81. [DOI: 10.1007/s00431-014-2408-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
34 Shiragami M, Mizukami A, Leeuwenkamp O, Mrkvan T, Delgleize E, Kurono Y, Iwata S. Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children. Infect Dis Ther 2014. [PMID: 25527448 DOI: 10.1007/s40121-014-0053-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
35 Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis 2014;59:1724-32. [PMID: 25159581 DOI: 10.1093/cid/ciu683] [Cited by in Crossref: 123] [Cited by in F6Publishing: 104] [Article Influence: 15.4] [Reference Citation Analysis]
36 Korppi M, Karppa H, Vuento R. Universal pneumococcal vaccination of <2-year-olds decreased pneumococcal bacteremia and antibiotic resistance in <5-year-olds. Acta Paediatr 2013;102:e239-40. [DOI: 10.1111/apa.12243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
37 Ben-shimol S, Greenberg D, Hazan G, Givon-lavi N, Gottesman G, Grisaru-soen G, Dagan R. Differential Impact of Pneumococcal Conjugate Vaccines on Bacteremic Pneumonia Versus Other Invasive Pneumococcal Disease. Pediatric Infectious Disease Journal 2015;34:409-16. [DOI: 10.1097/inf.0000000000000604] [Cited by in Crossref: 19] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
38 Protasova IN, Wan TW, Bakhareva NV, Hung WC, Higuchi W, Iwao Y, Yelistratova TA, Ilyenkova NA, Sokolovskaya YS, Martynova GP, Reva IV, Reva GV, Sidorenko SV, Teng LJ, Peryanova OV, Salmina AB, Yamamoto T. Molecular characterization of Streptococcus pneumoniae, particularly serotype19A/ST320, which emerged in Krasnoyarsk, Russia. Microbiol Immunol 2017;61:359-70. [PMID: 28736993 DOI: 10.1111/1348-0421.12503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
39 Bosch AATM, van Houten MA, Bruin JP, Wijmenga-Monsuur AJ, Trzciński K, Bogaert D, Rots NY, Sanders EAM. Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands. Vaccine 2016;34:531-9. [PMID: 26667610 DOI: 10.1016/j.vaccine.2015.11.060] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
40 Ceyhan M, Ozsurekci Y, Gürler N, Öksüz L, Aydemir S, Ozkan S, Yuksekkaya S, Keser Emiroglu M, Gültekin M, Yaman A, Kiremitci A, Yanık K, Karli A, Ozcinar H, Aydin F, Bayramoglu G, Zer Y, Gulay Z, Gayyurhan ED, Gül M, Özakın C, Güdücüoğlu H, Perçin D, Akpolat N, Ozturk C, Camcıoğlu Y, Karadağ Öncel E, Çelik M, Şanal L, Uslu H. Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008-2014. Hum Vaccin Immunother 2016;12:308-13. [PMID: 26325175 DOI: 10.1080/21645515.2015.1078952] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
41 Koutouzis EI, Daikos GL, Chatzichristou P, Michos AG, Koutouzi FI, Chrousos GP, Syriopoulou VP. Characteristics of Streptococcus pneumoniae serotype 19A isolates from children in the pre and post Conjugate Vaccine Era. Single center experience 1986–2015. Vaccine 2018;36:5245-50. [DOI: 10.1016/j.vaccine.2018.07.055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Ceyhan M, Aykac K, Gurler N, Ozsurekci Y, Öksüz L, Altay Akısoglu Ö, Öz FN, Emiroglu M, TurkDagi H, Yaman A, Söyletir G, Öztürk C, Akpolat N, Özakin C, Aydın F, Aydemir Ş, Kiremitci A, Gültekin M, Camcıoglu Y, Zer Y, Güdücüoğlu H, Gülay Z, Birinci A, Arabaci C, Karbuz A, Devrim I, Sorguc Y, Baysan BÖ, Karadag Oncel E, Yilmaz N, Altintop YA. Serotype distribution of Streptococcus pneumonia in children with invasive disease in Turkey: 2015-2018. Hum Vaccin Immunother 2020;16:2773-8. [PMID: 32530357 DOI: 10.1080/21645515.2020.1747931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Ben-shimol S, Givon-lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media. Clin Infect Dis 2016;63:611-8. [DOI: 10.1093/cid/ciw347] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 10.8] [Reference Citation Analysis]
44 Mayanskiy N, Alyabieva N, Ponomarenko O, Lazareva A, Katosova L, Ivanenko A, Kulichenko T, Namazova-Baranova L, Baranov A. Serotypes and antibiotic resistance of non-invasive Streptococcus pneumoniae circulating in pediatric hospitals in Moscow, Russia. Int J Infect Dis 2014;20:58-62. [PMID: 24462930 DOI: 10.1016/j.ijid.2013.11.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
45 Lindstrand A, Galanis I, Darenberg J, Morfeldt E, Naucler P, Blennow M, Alfvén T, Henriques-Normark B, Örtqvist Å. Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8years after vaccine introduction in Stockholm, Sweden. Vaccine 2016;34:4565-71. [PMID: 27473304 DOI: 10.1016/j.vaccine.2016.07.031] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
46 Gil E, Noursadeghi M, Brown JS. The clinical and ecological impact of childhood pneumococcal vaccination. Br J Hosp Med (Lond) 2013;74:212-6. [PMID: 23571392 DOI: 10.12968/hmed.2013.74.4.212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 dos Santos SR, Passadore LF, Takagi EH, Fujii CM, Yoshioka CR, Gilio AE, Martinez MB. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation. Vaccine 2013;31:6150-4. [PMID: 23747454 DOI: 10.1016/j.vaccine.2013.05.042] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
48 Mamede LD, de Paula KG, de Oliveira B, Dos Santos JSC, Cunha LM, Junior MC, Jung LRC, Taranto AG, de Oliveira Lopes D, Leclercq SY. Reverse and structural vaccinology approach to design a highly immunogenic multi-epitope subunit vaccine against Streptococcus pneumoniae infection. Infect Genet Evol 2020;85:104473. [PMID: 32712314 DOI: 10.1016/j.meegid.2020.104473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Fu J, Li L, Liang Z, Xu S, Lin N, Qin P, Ye X, McGrath E. Etiology of acute otitis media and phenotypic-molecular characterization of Streptococcus pneumoniae isolated from children in Liuzhou, China. BMC Infect Dis 2019;19:168. [PMID: 30770718 DOI: 10.1186/s12879-019-3795-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
50 Sigurdsson S, Erlendsdóttir H, Quirk SJ, Kristjánsson J, Hauksson K, Andrésdóttir BDI, Jónsson AJ, Halldórsson KH, Sæmundsson Á, Ólason ÓH, Hrafnkelsson B, Kristinsson KG, Haraldsson Á. Pneumococcal vaccination: Direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children. Vaccine 2017;35:5242-8. [PMID: 28823621 DOI: 10.1016/j.vaccine.2017.08.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
51 Siira L, Jalava J, Kaijalainen T, Ollgren J, Lyytikäinen O, Virolainen A. Antimicrobial Resistance in Relation to Sero- and Genotypes Among Invasive Streptococcus pneumoniae in Finland, 2007–2011. Microbial Drug Resistance 2014;20:124-30. [DOI: 10.1089/mdr.2013.0156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
52 Hon KL, Fu A, Leung TF, Poon TC, Cheung WH, Fong CY, Ho YT, Lee TY, Ng TM, Yu WL, Cheung KL, Lee V, Ip M. Cardiopulmonary morbidity of streptococcal infections in a PICU. Clin Respir J 2015;9:45-52. [PMID: 24406041 DOI: 10.1111/crj.12103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
53 Kilpi T, Jokinen J, Puumalainen T, Nieminen H, Ruokokoski E, Rinta-kokko H, Traskine M, Lommel P, Moreira M, Ruiz-guinazu J, Borys D, Schuerman L, Palmu A. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial. Vaccine 2018;36:5891-901. [DOI: 10.1016/j.vaccine.2018.08.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
54 Ciancotti Oliver LR, Huertas Zarco I, Pérez Pérez E, Carmona Martí E, Carbó Malonda R, Gil Bru A, González Moran F. Enfermedad neumocócica invasiva en la Comunitat Valenciana. Seis años de vigilancia (2007-2012). Enfermedades Infecciosas y Microbiología Clínica 2015;33:149-55. [DOI: 10.1016/j.eimc.2014.05.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
55 Altun HU, Hascelik G, Gür D, Eser ÖK. Invasive pneumococci before the introduction of pneumococcal conjugate vaccine in Turkey: antimicrobial susceptibility, serotype distribution, and molecular identification of macrolide resistance. J Chemother 2015;27:74-9. [PMID: 24548097 DOI: 10.1179/1973947814Y.0000000176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
56 de Waure C, Specchia ML, Capizzi S, Aljicevic M, Dujovic M, Malaj A, Ricciardi W. Effectiveness of 7-valent pneumococcal conjugate vaccine: A meta-analysis of post-marketing studies. World J Meta-Anal 2015; 3(3): 151-162 [DOI: 10.13105/wjma.v3.i3.151] [Reference Citation Analysis]
57 Venables L, Govender S, Oosthuizen V. Heterologous expression and purification of biologically active domains 3 and 4 of human polymeric immunoglobulin receptor and its interaction with choline binding protein A of Streptococcus pneumoniae. Protein Expression and Purification 2013;91:207-14. [DOI: 10.1016/j.pep.2013.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Yahiaoui RY, Bootsma HJ, den Heijer CDJ, Pluister GN, John Paget W, Spreeuwenberg P, Trzcinski K, Stobberingh EE. Distribution of serotypes and patterns of antimicrobial resistance among commensal Streptococcus pneumoniae in nine European countries. BMC Infect Dis 2018;18:440. [PMID: 30157780 DOI: 10.1186/s12879-018-3341-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
59 Tamir SO, Roth Y, Dalal I, Goldfarb A, Grotto I, Marom T. Changing Trends of Acute Otitis Media Bacteriology in Central Israel in the Pneumococcal Conjugate Vaccines Era. Pediatric Infectious Disease Journal 2015;34:195-9. [DOI: 10.1097/inf.0000000000000536] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
60 Cohen R, Cohen JF, Chalumeau M, Levy C. Impact of pneumococcal conjugate vaccines for children in high- and non–high-income countries. Expert Review of Vaccines 2017;16:625-40. [DOI: 10.1080/14760584.2017.1320221] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
61 Yahiaoui RY, den Heijer CDj, van Bijnen EM, Paget WJ, Pringle M, Goossens H, Bruggeman CA, Schellevis FG, Stobberingh EE; APRES Study Team. Prevalence and antibiotic resistance of commensal Streptococcus pneumoniae in nine European countries. Future Microbiol 2016;11:737-44. [PMID: 27191588 DOI: 10.2217/fmb-2015-0011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
62 Marimón JM, Ercibengoa M, Santacatterina E, Alonso M, Pérez-Trallero E. Single-Step Multiplex PCR Assay for Determining 92 Pneumococcal Serotypes. J Clin Microbiol 2016;54:2197-200. [PMID: 27280423 DOI: 10.1128/JCM.01156-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
63 Principi N, Esposito S. Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines. Hum Vaccin Immunother 2015;11:1494-500. [PMID: 25970715 DOI: 10.1080/21645515.2015.1033600] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
64 Okade H, Funatsu T, Eto M, Furuya Y, Mizunaga S, Nomura N, Mitsuyama J, Yamagishi Y, Mikamo H. Impact of the pneumococcal conjugate vaccine on serotype distribution and susceptibility trends of pediatric non-invasive Streptococcus pneumoniae isolates in Tokai, Japan over a 5-year period. J Infect Chemother 2014;20:423-8. [PMID: 24802765 DOI: 10.1016/j.jiac.2014.03.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
65 Hernández-Bou S, Gómez B, Mintegi S, García-García JJ; Bacteraemia Study Working Group of the Infectious Diseases Working Group of the Spanish Society of Paediatric Emergencies (SEUP). Occult bacteremia etiology following the introduction of 13-valent pneumococcal conjugate vaccine: a multicenter study in Spain. Eur J Clin Microbiol Infect Dis 2018;37:1449-55. [PMID: 29736610 DOI: 10.1007/s10096-018-3270-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Urbancikova I, Prymula R, Goldblatt D, Roalfe L, Prymulova K, Kosina P. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. Vaccine 2017;35:5186-93. [PMID: 28797727 DOI: 10.1016/j.vaccine.2017.07.103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
67 Ngo CC, Massa HM, Thornton RB, Cripps AW. Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic Review. PLoS One 2016;11:e0150949. [PMID: 26953891 DOI: 10.1371/journal.pone.0150949] [Cited by in Crossref: 98] [Cited by in F6Publishing: 85] [Article Influence: 16.3] [Reference Citation Analysis]
68 Paulke-Korinek M, Kollaritsch H, Kundi M, Schmidle-Loss B, Zwazl I, Laaber B, Lakovits K, Vecsei A, Wiedermann U, Burgmann H. Characteristics of invasive pneumococcal disease in hospitalized children in Austria. Eur J Pediatr 2014;173:469-76. [PMID: 24221605 DOI: 10.1007/s00431-013-2193-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
69 Tsaban G, Ben-Shimol S. Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature. Vaccine 2017;35:2882-91. [PMID: 28449971 DOI: 10.1016/j.vaccine.2017.04.032] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 12.2] [Reference Citation Analysis]
70 Camilli R, Daprai L, Cavrini F, Lombardo D, D'Ambrosio F, Del Grosso M, Vescio MF, Landini MP, Pascucci MG, Torresani E, Garlaschi ML, Sambri V, Pantosti A. Pneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy. PLoS One 2013;8:e76309. [PMID: 24124543 DOI: 10.1371/journal.pone.0076309] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
71 Maestro B, Sanz JM. Choline Binding Proteins from Streptococcus pneumoniae: A Dual Role as Enzybiotics and Targets for the Design of New Antimicrobials. Antibiotics (Basel) 2016;5:E21. [PMID: 27314398 DOI: 10.3390/antibiotics5020021] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
72 Roig-Molina E, Sánchez-Angulo M, Seele J, García-Asencio F, Nau R, Sanz JM, Maestro B. Searching for Antipneumococcal Targets: Choline-Binding Modules as Phagocytosis Enhancers. ACS Infect Dis 2020;6:954-74. [PMID: 32135064 DOI: 10.1021/acsinfecdis.9b00344] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
73 Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther 2014;31:1011-44. [PMID: 25300593 DOI: 10.1007/s12325-014-0157-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
74 Weil-Olivier C, Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults? Vaccine 2014;32:2022-6. [PMID: 24565755 DOI: 10.1016/j.vaccine.2014.02.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
75 Desmet S, Verhaegen J, Van Ranst M, Peetermans W, Lagrou K. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? The Lancet Infectious Diseases 2018;18:830-1. [DOI: 10.1016/s1473-3099(18)30346-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 8] [Article Influence: 8.3] [Reference Citation Analysis]
76 Krenke K, Urbankowska E, Urbankowski T, Lange J, Kulus M. Clinical characteristics of 323 children with parapneumonic pleural effusion and pleural empyema due to community acquired pneumonia. J Infect Chemother 2016;22:292-7. [PMID: 26919911 DOI: 10.1016/j.jiac.2016.01.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
77 Kobierecka PA, Wyszyńska AK, Gubernator J, Kuczkowski M, Wiśniewski O, Maruszewska M, Wojtania A, Derlatka KE, Adamska I, Godlewska R, Jagusztyn-Krynicka EK. Chicken Anti-Campylobacter Vaccine - Comparison of Various Carriers and Routes of Immunization. Front Microbiol 2016;7:740. [PMID: 27242755 DOI: 10.3389/fmicb.2016.00740] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
78 Liu C, Xiong X, Xu W, Sun J, Wang L, Li J. Serotypes and patterns of antibiotic resistance in strains causing invasive pneumococcal disease in children less than 5 years of age. PLoS One 2013;8:e54254. [PMID: 23342111 DOI: 10.1371/journal.pone.0054254] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
79 Zhu F, Hu Y, Li J, Ye Q, Young MM, Zhou X, Chen Z, Yan B, Liang JZ, Gruber WC, Giardina PC, Scott DA. Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China. Pediatric Infectious Disease Journal 2016;35:999-1010. [DOI: 10.1097/inf.0000000000001248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
80 Tóthpál A, Laub K, Kardos S, Tirczka T, Kocsis A, VAN DER Linden M, Dobay O. Epidemiological analysis of pneumococcal serotype 19A in healthy children following PCV7 vaccination. Epidemiol Infect 2016;144:1563-73. [PMID: 26548594 DOI: 10.1017/S0950268815002757] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
81 Ramos V, Parra EL, Duarte C, Moreno J. Characterization of Streptococcus pneumoniae invasive serotype 19A isolates recovered in Colombia. Vaccine 2014;32:755-8. [PMID: 24374499 DOI: 10.1016/j.vaccine.2013.12.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
82 Quirk SJ, Haraldsson G, Hjálmarsdóttir MÁ, van Tonder AJ, Hrafnkelsson B, Bentley SD, Haraldsson Á, Erlendsdóttir H, Brueggemann AB, Kristinsson KG. Vaccination of Icelandic Children with the 10-Valent Pneumococcal Vaccine Leads to a Significant Herd Effect among Adults in Iceland. J Clin Microbiol 2019;57:e01766-18. [PMID: 30651396 DOI: 10.1128/JCM.01766-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
83 Wu DB, Chaiyakunapruk N, Chong HY, Beutels P. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014). Vaccine 2015;33:1633-58. [PMID: 25681663 DOI: 10.1016/j.vaccine.2015.01.081] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
84 Fortunato F, Martinelli D, Cappelli MG, Cozza V, Prato R. Impact of Pneumococcal Conjugate Universal Routine Vaccination on Pneumococcal Disease in Italian Children. J Immunol Res 2015;2015:206757. [PMID: 26351644 DOI: 10.1155/2015/206757] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
85 Echaniz-Aviles G, Soto-Nogueron A, Miranda-Novales G, Carnalla-Barajas MN, Velazquez-Meza ME, Solórzano-Santos F; SIREVA Network–Mexico. Streptococcus pneumoniae Serotypes Identified in Mexican Children with Invasive Disease Before and After the Introduction of PCV7 (1993-2012). Arch Med Res 2015;46:149-53. [PMID: 25743930 DOI: 10.1016/j.arcmed.2015.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
86 Marimón JM, Morales M, Gamen S, Manrique A, Ercibengoa M, Cilla G. A reverse-hybridization test for the identification of 76 pneumococcal serotypes, 42 individually and 34 in pairs. J Microbiol Methods 2017;143:13-6. [PMID: 28818600 DOI: 10.1016/j.mimet.2017.08.010] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
87 Tin Tin Htar M, Morato Martínez J, Theilacker C, Schmitt HJ, Swerdlow D. Serotype evolution in Western Europe: perspectives on invasive pneumococcal diseases (IPD). Expert Rev Vaccines 2019;18:1145-55. [PMID: 31682762 DOI: 10.1080/14760584.2019.1688149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
88 Malchrzak W, Mastalerz-Migas A. Epidemiologic Benefits of Pneumococcal Vaccine Introduction into Preventive Vaccination Programs. Adv Exp Med Biol 2021;1324:11-9. [PMID: 33136238 DOI: 10.1007/5584_2020_589] [Reference Citation Analysis]
89 Plosker GL. 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Infants, Children, and Adolescents. Pediatr Drugs 2013;15:403-23. [DOI: 10.1007/s40272-013-0047-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
90 Lagousi T, Papadatou I, Kopsidas I, Critselis E, Theodoridou M, Spoulou V. Epidemiology of Community-Acquired Pneumonia Hospitalizations and Associated Complications Before and After the Implementation of the Heptavalent Pneumococcal Conjugate Vaccine in Athens, Greece. J Pediatric Infect Dis Soc 2015;4:260-3. [PMID: 26407430 DOI: 10.1093/jpids/pit088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Hütter J, Lepenies B. Carbohydrate-Based Vaccines: An Overview. Methods Mol Biol 2015;1331:1-10. [PMID: 26169731 DOI: 10.1007/978-1-4939-2874-3_1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
92 Furuya Y, Yamagishi Y, Okade H, Kadota T, Funatsu T, Eto M, Nomura N, Mitsuyama J, Mikamo H. Impact of the pneumococcal conjugate vaccine on serotype distribution of adult non-invasive Streptococcus pneumoniae isolates in Tokai region, Japan, 2008-2016. J Infect Chemother 2017;23:394-9. [PMID: 28427991 DOI: 10.1016/j.jiac.2017.03.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Wagner-Muñiz DA, Haughney SL, Kelly SM, Wannemuehler MJ, Narasimhan B. Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity. Front Immunol 2018;9:325. [PMID: 29599766 DOI: 10.3389/fimmu.2018.00325] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
94 Lee LH, Gu XX, Nahm MH. Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention. Vaccines (Basel) 2014;2:112-28. [PMID: 26344470 DOI: 10.3390/vaccines2010112] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
95 Plosker GL. 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D-Conjugate Vaccine: A Review in Infants and Children. Pediatr Drugs 2014;16:425-44. [DOI: 10.1007/s40272-014-0089-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]